CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and release growth hormone. It exists in two forms: CJC-1295 with DAC, which has a half-life of 5.8-8.1 days due to albumin binding, and CJC-1295 without DAC (also called modified GRF 1-29 or mod GRF 1-29), which has a half-life of approximately 30 minutes. Neither form is FDA-approved for any indication.

The DAC (Drug Affinity Complex) version uses a maleimidopropionic acid linker to bind to serum albumin, extending its half-life to 5.8-8.1 days and allowing weekly dosing. Without DAC (mod GRF 1-29), the half-life is about 30 minutes, producing discrete GH pulses that more closely mimic the body's natural rhythm. The no-DAC version is more widely used because side effects clear faster and the pulsatile pattern is considered more physiologic. The DAC version appeals to those who prefer less frequent injections.

CJC-1295 stimulates the body's own growth hormone production through the pituitary gland, while HGH replaces growth hormone directly with an exogenous source. CJC-1295 preserves the somatostatin feedback loop, reducing the risk of acute supraphysiologic GH peaks. HGH bypasses this feedback, producing flat elevated levels that suppress natural production. However, sustained GH/IGF-1 elevation from CJC-1295 can still cause insulin resistance and fluid retention even with feedback intact. CJC-1295 is significantly less expensive but produces more gradual results. HGH is FDA-approved for specific conditions and is a controlled substance.

CJC-1295 and ipamorelin target two different receptor pathways — CJC-1295 activates the GHRH receptor while ipamorelin activates the ghrelin receptor (GHS-R1a). When combined, they produce amplified GH release through dual-pathway stimulation. Ipamorelin is notable for selectivity: it releases GH without elevating cortisol or prolactin even at very high doses, unlike other GH releasing peptides (PMID: 9849822). The combination is the most widely used GH secretagogue protocol.

CJC-1295's legal status is in flux as of early 2026. It was placed on the FDA Category 2 list in late 2023, effectively banning compounding. In February 2026, HHS Secretary RFK Jr. announced that approximately 14 of 19 restricted peptides would return to legal compounding, but the specific list has not been officially published. CJC-1295's inclusion is uncertain due to cardiac concerns flagged by the FDA. It is not FDA-approved, not a controlled substance, and is prohibited by WADA for athletes at all times.

The most frequently reported side effects are facial flushing and warmth shortly after injection (nearly universal in early weeks, subsides with continued use), water retention and puffiness particularly in the morning, headaches during the first 1-2 weeks, and injection site reactions. Less common effects include numbness or tingling in the hands, increased appetite (more common when stacked with ipamorelin), and vivid dreams. The FDA has flagged cardiac concerns, and one death occurred during a Phase II trial of the DAC version, though causation was not confirmed.

Based on clinical data and community reports, sleep improvement is typically the first noticeable effect, often within the first 1-2 weeks. Energy and recovery improvements are commonly reported at weeks 2-4. Visible body composition changes — reduced abdominal fat, improved muscle tone — typically emerge at 4-8 weeks. Significant lean muscle gain, fat loss, and anti-aging skin benefits are reported at 3-6 months. The GHRH class requires consistent use over months to see full effects, as GH mediates gradual tissue remodeling rather than acute changes.

For the no-DAC version, bedtime injection on an empty stomach is the most widely recommended timing. This aligns with the body's natural nocturnal GH pulse, which occurs during the first 90 minutes of deep sleep. Fasting for at least 2 hours before injection is considered important, as food intake — particularly carbohydrates and fats — can blunt the GH response. Most protocols recommend waiting 30-60 minutes after injection before eating. The DAC version is less timing-dependent due to its multi-day half-life.

There is no direct evidence linking CJC-1295 specifically to cancer in humans. However, GH and IGF-1 have known mitogenic (cell-growth-promoting) properties, which creates a theoretical concern that sustained elevation could promote growth of existing tumors. A systematic review noted that long-term cancer incidence and mortality data for GH secretagogues as a class are lacking (PMID: 28400207). Most clinicians advise against GH secretagogue use in individuals with active cancer or a strong family history of hormone-sensitive cancers.

Yes, with an important caveat. A controlled study showed that even the DAC version preserves GH pulse frequency and magnitude — the pituitary's rhythmic pattern continues (PMID: 17018654). However, the basal GH floor was elevated 7.5-fold, meaning the pulse pattern sits on a significantly elevated baseline rather than at normal resting levels. The no-DAC version produces discrete pulses that return closer to baseline and is considered more physiologically natural. Both forms maintain the somatostatin feedback loop, which is a meaningful safety distinction from exogenous HGH.

In July 2006, a Phase II trial of CJC-1295 DAC for HIV-associated lipodystrophy was halted after a participant died hours after his 11th injection at an Argentine study site. The cause of death was confirmed as acute myocardial infarction. The attending physician attributed it to pre-existing asymptomatic coronary artery disease unrelated to the drug. The trial had enrolled 192 HIV-positive participants with elevated cardiovascular risk. ConjuChem went bankrupt without completing the trial. The FDA flagged cardiac concerns when reviewing CJC-1295 during the 2024 PCAC process, indicating the signal was not fully dismissed at the regulatory level.

Through compounding pharmacies and telehealth clinics (when available), CJC-1295/ipamorelin combination programs typically cost $200-400 per month for the peptide alone, or $249-675 per month through full-service clinic programs that include consultations and monitoring. Individual CJC-1295 vials from research suppliers range from $30-80 but carry no purity guarantee and no medical oversight. For comparison, synthetic HGH costs $800-3,000+ per month, sermorelin $200-500, and oral MK-677 $50-100.

The no-DAC version (mod GRF 1-29) is more widely used and generally preferred for several reasons: it produces pulsatile GH release that better mimics the body's natural pattern, side effects clear within hours rather than days, dose adjustments take effect immediately, and the risk of receptor desensitization may be lower. The DAC version is preferred mainly by those who want the convenience of 1-2 injections per week instead of daily dosing. If you experience side effects with the DAC version, they may persist for several days due to its long half-life.

Growth hormone can decrease insulin sensitivity, and this is a recognized concern with all GH secretagogues. A systematic review noted potential blood glucose increases with GH secretagogue use (PMID: 28400207). This effect is more pronounced with the DAC version due to sustained GH elevation. Pre-diabetic or insulin-resistant individuals should monitor blood glucose if using CJC-1295. The 16-week Khorram trial noted improved insulin sensitivity in men receiving a GHRH analog, suggesting effects may be complex and population-dependent (PMID: 9141536).

Add bacteriostatic water (not sterile water — bacteriostatic water contains a preservative for multi-use vials) to the lyophilized powder. Direct the water stream against the vial wall rather than onto the powder cake. Gently swirl the vial until dissolved — never shake, as this can damage the peptide structure. Refrigerate immediately after reconstitution at 36-46F. Reconstituted CJC-1295 typically remains stable for 14-28 days when properly refrigerated. Never freeze reconstituted peptide, and discard any solution that appears cloudy or contains particles.

Sleep improvement is the most consistently and earliest reported benefit of CJC-1295, aligning with GHRH class research. A clinical study showed that GHRH administered during the third REM period increased slow-wave sleep nearly 10-fold (PMID: 8476038). Community users typically report deeper sleep, fewer nighttime awakenings, and more vivid dreams within the first 1-2 weeks. The sleep benefit appears to be a class effect of GHRH agonists rather than specific to CJC-1295.

Both are GHRH analogs that stimulate natural GH production, but they differ in pharmacokinetics and regulatory history. Sermorelin (GRF 1-29) has a half-life of 10-20 minutes and is the minimum active GHRH fragment. CJC-1295 no-DAC (mod GRF 1-29) has improved stability with a ~30-minute half-life due to four amino acid substitutions. CJC-1295 DAC has a 5.8-8.1 day half-life. Sermorelin was formerly FDA-approved (Geref, withdrawn 2008 for commercial reasons) and was never placed on the Category 2 list. CJC-1295 has never been FDA-approved and was placed on Category 2.

Cycling is commonly recommended in clinical and community protocols, though specific cycling data for CJC-1295 is limited. The most discussed schedule is 12-16 weeks on followed by 4-6 weeks off. Within a cycle, some protocols use a 5-days-on, 2-days-off weekly pattern to reduce potential GHRH receptor desensitization. The rationale is that continuous GHRH receptor stimulation may lead to reduced sensitivity over time. Some protocols use MK-677 (an oral GH secretagogue working through a different receptor) during off-cycle periods to maintain IGF-1 levels while allowing GHRH receptor recovery.